Hypertension

Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

Idorsia Ltd. announced the FDA's approval of aprocitentan (Tryvio) for treatment-resistant hypertension on March 20, 2024.

Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.

In new topline results from the KARDIA-2 trial, zilebesiran added to standard-of-care antihypertensive treatments showed significant reductions in systolic blood pressure.

Older adults who use a salt substitute had a 40% lower incidence of experiencing hypertension than people who use regular salt.

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

On January 25, 2024, the day following the proposed PDUFA goal date, Liquidia Corporation announced the FDA was still reviewing the NDA for pulmonary hypertension with interstitial lung disease for treprostinil inhalation powder (Yutrepia).

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

The FDA has approved the second renal denervation device in the agency's history with the approval of Medtronic's Symplicity Spyral system.

Lowering blood pressure significantly reduced the risk of developing dementia among adults with hypertension in China compared to usual care.

The phase 2 KARDIA-1 study reports a single dose of zilebesiran safely reduced systolic blood pressure in people with mild-to-moderate hypertension for up to 6 months.

On November 7, 2023, Recor Medical announced the FDA approval of their Paradise Ultrasound Renal Denervation system for the treatment of hypertension.

Richard Johnson, MD, discusses the results of a study from ASN Kidney Week 2023 detailing the effects of urate-lowering therapy on blood pressure among patients with gout.

An analysis of Target-HTN provides new insight into the effects of lorundrostat among patients with uncontrolled or treatment-resistant hypertension.

An analysis of more than 1 million men found higher blood pressure in late adolescence was associated with an increased risk for major cardiovascular events in later life.

In their latest recommendation statement, the USPSTF recommends blood pressure screening for all pregnant individuals to detect hypertensive disorders.

New data from a dose-finding trial suggests the aldosterone synthase inhibitor lorundrostat could find a role in the management of resistant or uncontrolled hypertension.

At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with PAH.

On September 7, 2023, Alnylam Pharmaceuticals announced positive topline data from the phase 2 KARDIA-1 trial of zilbesiran in the treatment of hypertension.

The FDA Circulatory System Devices Panel has voted in favor of the benefit-risk profile of Recor Medical's RDN system in a 10-2 vote but declined to endorse Medtronic's system in a 6-7 vote.

Hypertension prevalence was significantly higher among adults with obesity and severe NAFLD, providing important information related to the association between hypertension and NAFLD severity.

An analysis of data from a NYC-based health system indicate more than 1 in 5 people hospitalized for COVID-19 and 1 in 10 nonhospitalized COVID-19 patients went on to develop persistent hypertension 6 months later.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

An analysis of 7 international, longitudinal studies with nearly 20,000 patients details apparent increases in risk associated with daily alcohol consumption among healthy adults.

A multipart, phase 1 trial provides evidence demonstrating the safety of zilebesiran, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.

A new analysis presented at ADA 2023 recommended effective diabetic retinopathy screening for patients with T2D and hypertension.

However, results from the Vet-COACH trial reported a significant improvement in mental health–related quality of life in the intervention group compared with the control group.

Data from the SPRINT MIND trial suggests intensive blood pressuring-lowering was associated with slower increases in white matter lesions and improved cerebral blood flow.